Scholar Rock Holding (SRRK) Amortization of Deferred Charges (2019 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Amortization of Deferred Charges of $1.5 million for Q1 2026, up 24.09% year-over-year from $1.2 million in Q1 2025, and up 11.19% quarter-over-quarter from $1.4 million in Q4 2025.
Powered by 
Analysis
Scholar Rock Holding (SRRK) Amortization of Deferred Charges (2019 - 2026) Analysis & Trends
Scholar Rock Holding's Amortization of Deferred Charges history runs 8 years deep, the most recent figure standing at $1.5 million for Q1 2026.
- In Q1 2026, Amortization of Deferred Charges rose 24.09% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $5.6 million (down 12.95% YoY), while the FY2025 annual figure was $5.3 million, up 0.73% from the prior year.
- Amortization of Deferred Charges for Q1 2026 stood at $1.5 million, up from $1.4 million in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $6.9 million in Q4 2023, with the low at -$3.4 million in Q3 2023.
- The 5-year median for Amortization of Deferred Charges is $1.3 million (2025), against an average of $1.2 million.
- The sharpest annual moves came in 2023 and 2024: Amortization of Deferred Charges surged 4601.36% in 2023, then plunged 96.86% in 2024.
- Scholar Rock Holding's Amortization of Deferred Charges stood at $147000.0 in 2022, then soared by 4601.36% to $6.9 million in 2023, then decreased by 27.39% to $5.0 million in 2024, then sank by 72.4% to $1.4 million in 2025, then climbed by 11.19% to $1.5 million in 2026.
- Business Quant data shows SRRK's Amortization of Deferred Charges at $1.5 million in Q1 2026, $1.4 million in Q4 2025, and $1.3 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | Scholar Rock Holding | 7.19 Bn | 7.19 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 109,000.00 |
| Mar 31, 2026 | 34,000.00 |
| Dec 31, 2025 | 98,000.00 |
| Sep 30, 2025 | -137,000.00 |
| Jun 30, 2025 | 14,000.00 |
| Mar 31, 2025 | 448,000.00 |
| Dec 31, 2024 | 47,000.00 |
| Sep 30, 2024 | 71,000.00 |
| Jun 30, 2024 | 58,000.00 |
| Mar 31, 2024 | 77,000.00 |
| Dec 31, 2023 | 59,000.00 |
| Sep 30, 2023 | 58,000.00 |
| Jun 30, 2023 | 72,000.00 |
| Mar 31, 2023 | 85,000.00 |
| Dec 31, 2022 | 147,000.00 |
| Sep 30, 2022 | 184,000.00 |
| Jun 30, 2022 | 191,000.00 |
| Mar 31, 2022 | 198,000.00 |
| Dec 31, 2021 | 87,000.00 |
| Sep 30, 2021 | 81,000.00 |